The mechanism of tau toxicity is still unclear. Here we report that recombinant tau oligomers and monomers, intraventricularly injected in mice with a pure human tau background, foster tau pathology through different mechanisms. Oligomeric forms of tau alter the conformation of tau in a paired helical filament-like manner. This effect occurs without tau hyperphosphorylation as well as activation of specific kinases, suggesting that oligomers of tau induce tau assembly through a nucleation effect. Monomers, in turn, induce neurodegeneration through a calpain-mediated tau cleavage that leads to accumulation of a 17 kDa neurotoxic peptide and induction of apoptotic cell death.
MorrisM, MaedaS, VosselK, MuckeL (2011) The many faces of tau. Neuron70, 410–426.
2.
ManasseroG, GuglielmottoM, ZamfirR, BorghiR, ColomboL, SalmonaM, PerryG, OdettiP, ArancioO, TamagnoE, TabatonM (2016) Beta-amyloid 1-42 monomers, but not oligomers, produce PHF-like conformation of tau protein. Aging Cell15, 914–923.
3.
FontaineSN, SabbaghJJ, BakerJ, Martinez-LichaCR, DarlingA, DickeyCA (2015) Cellular factors modulating the mechanism of tau protein aggregation. Cell Mol Life Sci72, 1863–1879.
4.
GoedertM (2015) Alzheimer’s and Parkinson’s diseases: The prion concept in relation to assembled Aβ, tau, and α-synuclein. Science349, 1255555.
5.
AndorferC, KressY, EspinozaM, de SilvaR, TuckerKL, BardeYA, DuffK, DaviesP (2003) Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem86, 582–590.
6.
FáM, PuzzoD, PiacentiniR, StaniszewskiA, ZhangH, BaltronsMA, Li PumaDD, ChatterjeeI, LiJ, SaeedF, BermanHL, RipoliC, GulisanoW, GonzalezJ, TianH, CostaJA, LopezP, DavidowitzE, YuWH, HaroutunianV, BrownLM, PalmeriA, SigurdssonEM, DuffKE, TeichAF, HonigLS, SierksM, MoeJG, D’AdamioL, GrassiC, KanaanNM, FraserPE, ArancioO (2016) Extracellular tau oligomers produce an immediate impairment of LTP and memory. Sci Rep6, 19393.
7.
FurukawaK, WangY, YaoPJ, FuW, MattsonMP, ItoyamaY, OnoderaH, D’SouzaI, PoorkajPH, BirdTD, SchellenbergGD (2003) Alteration in calcium channel properties is responsible for theneurotoxic action of a familial frontotemporal dementia taumutation. J Neurochem87, 427–436.
8.
WeaverCL, EspinozaM, KressY, DaviesP (2000) Conformational change as one of the earliest alterations of tau in Alzheimer’s disease. Neurobiol Aging21, 719–727.
9.
AlonsoA, ZaidiT, NovakM, Grundke-IqbalI, IqbalK (2001) Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments. Proc Natl Acad Sci U S A98, 6923–6928.
10.
HaaseC, StielerJT, ArendtT, HolzerM (2004) Pseudophosphorylation of tau protein alters its ability for self-aggregation. J Neurochem88, 1509–1520.
11.
LaFerlaFM (2002) Calcium dyshomeostasis and intracellular signalling in Alzheimer’s disease. Nat Rev Neurosci3, 862–872.
12.
JinN, YinX, GuJ, ZhangX, ShiJ, QianW, JiY, CaoM, GuX, DingF, IqbalK, GongCX, LiuF (2015) Truncation and activation of dual specificity tyrosine phosphorylation-regulated kinase 1A by calpain I: A molecular mechanism linked to tau pathology in Alzheimer disease. J Biol Chem290, 15219–15237.
13.
FerreiraA, BigioEH (2011) Calpain-mediated tau cleavage: A mechanism leading to neurodegeneration shared by multiple tauopathies. Mol Med17, 676–685.
14.
CzogallaA, SikorskiAF (2005) Spectrin and calpain: A ‘target’ and a ‘snier’ in the pathology of neuronal cells. Cell Mol Life Sci62, 1913–1924.
15.
Fernandez-MoralesJC, Arranz-TagarroJA, Calvo-GallardoE, MarotoM, PadinJF, GarciaAG (2012) Stabilizers of neuronal and mithocondrial calcium cycling as a strategy for developing a medicine for Alzheimer’s disease. ACS Chem Neurosci3, 873–883.
16.
JackCRJr, KnopmanDS, JagustWJ, PetersenRC, WeinerMW, AisenPS, ShawLM, VemuriP, WisteHJ, WeigandSD, LesnickTG, PankratzVS, DonohueMC, TrojanowskiJQ (2013) Tracking pathophysiologicalprocesses in Alzheimer’s disease: An updated hypothetical model ofdynamic biomarkers. Lancet Neurol12, 207–216.
HuttonM, LendonCL, RizzuP, BakerM, FroelichS, HouldenH, Pickering-BrownS, ChakravertyS, IsaacsA, GroverA, HackettJ, AdamsonJ, LincolnS, DicksonD, DaviesP, PetersenRC, StevensM, de GraaffE, WautersE, van BarenJ, HillebrandM, JoosseM, KwonJM, NowotnyP, CheLK, NortonJ, MorrisJC, ReedLA, TrojanowskiJ, BasunH, LannfeltL, NeystatM, FahnS, DarkF, TannenbergT, DoddPR, HaywardN, KwokJB, SchofieldPR, AndreadisA, SnowdenJ, CraufurdD, NearyD, OwenF, OostraBA, HardyJ, GoateA, van SwietenJ, MannD, LynchT, HeutinkP (1998) Association of missense and 5’-splice-site mutations in tau with the inherited dementia FTDP-17. Nature393, 702–705.
19.
SpillantiniMG, MurrellJR, GoedertM, FarlowMR, KlugA, GhettiB (1998) Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci U S A95, 7737–7741.
20.
CrewsL, MasliahE (2010) Molecular mechanisms of neurodegeneration in Alzheimer’s disease. Hum Mol Genet19, R12–20.
21.
MatsuoES, ShinRW, BillingsleyML, Van de VoordeA, O’ConnorM, TrojanowskiJQ, LeeVM (1994) Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer’s disease paired helical filament tau. Neuron13, 989–1002.
22.
YuY, RunX, LiangZ, LiY, LiuF, LiuY, IqbalK, Grundke-IqbalI, GongCX (2009) Developmental regulation of tau phosphorylation, tau kinases, and tauphosphatases. J Neurochem108, 1480–1494.
23.
PoolerAM, PhillipsEC, LauDH, NobleW, HangerDP (2013) Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Rep14, 389–394.
WuJW, HussainiSA, BastilleIM, RodriguezGA, MrejeruA, RilettK, SandersDW, CookC, FuH, BoonenRA, HermanM, NahmaniE, EmraniS, FigueroaYH, DiamondM, ClellandCL, WrayS, DuffKE (2016) Neuronal activity enhances tau propagation and tau pathology in vivo. Nat Neurosci19, 1085–1092.
26.
ParkSY, FerreiraA (2005) The generation of a 17 kDa neurotoxic fragment: An alternative mechanism by which tau mediates beta-amyloid-induced neurodegeneration. J Neurosci25, 5365–5375.
27.
ParkSY, TournellC, SinjoanuRC, FerreiraA (2007) Caspase-3- and calpain-mediated tau cleavage are differentially prevented by estrogen and testosterone in beta-amyloid-treated hippocampal neurons. Neuroscience144, 119–127.
28.
SinjoanuRC, KleinschmidtS, BitnerRS, BrioniJD, MoellerA, FerreiraA (2008) The novel calpain inhibitor A-705253 potentlyinhibits oligomeric beta-amyloid-induced dynamin 1 and taucleavage in hippocampal neurons. Neurochem Int53, 79–88.
29.
CanuN, DusL, BarbatoC, CiottiMT, BrancoliniC, RinaldiAM, NovakM, CattaneoA, BradburyA, CalissanoP (1998) Tau cleavage and dephosphorylation in cerebellar granule neurons undergoing apoptosis. J Neurosci18, 7061–7074.
30.
CanuN, CalissanoP (2003) In vitro cultured neurons for molecular studies correlating apoptosis with events related to Alzheimer disease. Cerebellum2, 270–278.
